American Society for Radiation Oncology

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Retrieved on: 
Tuesday, October 25, 2022
Research, Surgery, Genetics, Men, Biotechnology, General Health, Consumer, Health, Science, Oncology, Physician, CLIA, Disease, American Society for Radiation Oncology, Investor, Radiation, Diagnosis, Laboratory, Annual report, Society, Patient, Twitter, Man, Research, University, Prostate, ADT, RP, Industry, ASTRO, Radiation therapy, Urology, Health, Prostate cancer, Genomics, Recurrence, SRT, GRID, Clinical research, Forward-looking statement, Database, PSA, FDA, Biomarker, DNA repair, Medical imaging, Pharmaceutical industry, Medical device

(Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the companys Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP) would benefit from dose-intensified salvage radiotherapy (SRT).

Key Points: 
  • (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the companys Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP) would benefit from dose-intensified salvage radiotherapy (SRT).
  • Post-Operative Radiation Therapy Outcomes Score (PORTOS) is a gene-expression signature of 24 DNA damage, repair and immune pathway genes previously shown to predict benefit from postoperative radiotherapy.
  • The new data shared at ASTRO show that the subset of men with higher PORTOS scores had substantial improvement in clinical-progression-free survival (CPFS) with the higher dose of SRT (70Gy).
  • Dependent on further studies, this could be the first predictive biomarker to help physicians personalize radiotherapy dose in the postoperative prostate cancer setting.

Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Retrieved on: 
Monday, October 24, 2022
Biotechnology, FDA, Health, General Health, Radiology, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Physician, American Society for Radiation Oncology, Response evaluation criteria in solid tumors, Review, Radiation, New Drug Application, Population, RH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Patient, PSMA, Prostate-specific antigen, Man, Annual general meeting, Multimedia, DRS, Cancer, Food, Radiation therapy, ASTRO, Prostate cancer, Recurrence, PET, PSA, Radiopharmaceutical, Medical imaging, MD

The utility of conventional imaging for the localization of recurrence is limited, particularly in patients with low PSA levels.

Key Points: 
  • The utility of conventional imaging for the localization of recurrence is limited, particularly in patients with low PSA levels.
  • These findings from the SPOTLIGHT study showed high DRs by majority read for 18F-rhPSMA-7.3 PET over a wide range of baseline PSA levels.
  • Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: (SPOTLIGHT, NCT04186845 ), in men with recurrent disease and (LIGHTHOUSE, NCT04186819 ), in men with newly diagnosed prostate cancer.
  • In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies.

Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Oncology, LinkedIn, Papilloma, CLIA, College of American Pathologists, Risk, Mayo Clinic, Disease, American Society for Radiation Oncology, Head, Radiation, DART, TTMV, List of pathologists, Society, Patient, Biotechnology, Twitter, Annual general meeting, Cancer, III, DRS, MRD, Radiation therapy, ASTRO, Progression-free survival, Toxicity, CEO, College, Recurrence, HPV, OPSCC, DNA, Medical imaging, Pharmaceutical industry, Vaccine, Raoul de Navery

radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.

Key Points: 
  • radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.
  • The presence of MRD, both in the post-operative setting and at 3 months post-treatment, was significantly associated with shorter progression-free survival.
  • Results from the MC1675 trial were initially presented at the ASTRO 2021 annual meeting and follow-up is ongoing.
  • More information on Naveris and NavDx can be found at booth #2348, or look for highlights from #ASTRO22 Twitter and LinkedIn .

PreludeDx™ Presents DCISionRT® Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting

Retrieved on: 
Tuesday, October 25, 2022
Physician, LinkedIn, Molecular biology, Risk, Risk assessment, Decision tree, Woman, University of California, San Francisco, Society, Patient, Biology, Research, Twitter, Instagram, Precision medicine, Technology, University, OH, Company, National Cancer Institute, American Society for Radiation Oncology, Department, Radiation therapy, Breast cancer, CEO, Cleveland Clinic, Breast, National, Recurrence, Radiation, Ductal carcinoma, Clinical research, IBR, Biomarker, RT, Pharmaceutical industry, Medical imaging, Facebook, MD, ASTRO, DCIS

LAGUNA HILLS, Calif., Oct. 25, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior risk and RT benefit prediction compared to common clinicopathologic features. The data was presented in an oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, held on October 23 – 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

Key Points: 
  • The data was presented in an oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, held on October 23 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
  • "It is important to follow the clinical evidence when making the best treatment decisions with our patients.
  • "DCISionRT provides unique game-changing information to enable physicians and DCIS patients to confidently make a personalized treatment decision," said Dan Forche, President and CEO of PreludeDx.
  • DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit.

Promaxo to Showcase In-Office MRI System at ASTRO 2022 Annual Meeting

Retrieved on: 
Wednesday, October 19, 2022
Adoption, Science, Radiation, Diagnosis, Society, NUALS Arts and Literary Annual Meet, Research, Annual general meeting, MRI, Technology, Knowledge, Company, American Society for Radiation Oncology, AI, Radiation therapy, ASTRO, CEO, Health, GLOBE, Robotics, Medical imaging

OAKLAND, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, today announced exhibit booth activities showcasing its compact, in-office MRI system at the upcoming American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas on October 23 - 26, 2022.

Key Points: 
  • OAKLAND, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, today announced exhibit booth activities showcasing its compact, in-office MRI system at the upcoming American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas on October 23 - 26, 2022.
  • We are delighted to showcase our point of care MRI system at ASTRO this year following another quarter of strong execution, said Dr. Amit Vohra, Founder and CEO of Promaxo.
  • The Company is hosting an exhibit showcasing its patient-centric MRI platform at booth #3801 at ASTRO 2022.
  • The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

Retrieved on: 
Thursday, October 20, 2022
Oncology, Medical Devices, Health, Hospitals, Radiology, Biotechnology, American Society for Radiation Oncology, SRS, Workflow, Neoplasm, Society, Biology, Annual general meeting, Multimedia, Technology, Cancer, Radiation therapy, ASTRO, Control, Reflection, Positron, Medicine, IMRT, SBRT, PET, Radiation, X1, Medical imaging

Additionally, ASTRO will serve as the setting for introducing SCINTIX as the new product name for RefleXions flagship BgRT technology and treatment, provided only through the companys X1 platform.

Key Points: 
  • Additionally, ASTRO will serve as the setting for introducing SCINTIX as the new product name for RefleXions flagship BgRT technology and treatment, provided only through the companys X1 platform.
  • View the full release here: https://www.businesswire.com/news/home/20221020005009/en/
    RefleXion introduces SCINTIX as the new brand name for its flagship BgRT technology and treatment, provided only through the company's X1 platform.
  • The following presentations taking place during ASTRO 2022 evaluate the RefleXion X1 machine with SCINTIX technology:
    3301 IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System.
  • The RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).

Together with Siemens Healthineers, Varian Showcases Technologies and Services Spanning the Full Cancer Care Continuum at ASTRO 2022

Retrieved on: 
Thursday, October 20, 2022
Nova Scotia Health Authority, PALO, Thought, Machine learning, Annual, Radiographer, Treatment, Feasibility study, Strathcona County, Central Time, IMV, Society, Evidence-based medicine, Patient, Twitter, Program, AOS, Science, MRI, Partnership, Artificial intelligence, Cancer, Technology, CT, NUALS Arts and Literary Annual Meet, American Society of Radiologic Technologists, Goal, Solution, Google Images, American Society for Radiation Oncology, Doctor of Philosophy, Radiation therapy, ASTRO, CEO, Siemens Healthineers, ASRT, Clinical trial, Physics, Clinical research, Radiation, Ayala Corporation, Medical imaging, Pharmaceutical industry, Ethos, PET/CT, Varian

The combined company addresses the full cancer care continuum, and is working to create an oncology ecosystem to support care providers along the entire cancer care journey from screening to survivorship.

Key Points: 
  • The combined company addresses the full cancer care continuum, and is working to create an oncology ecosystem to support care providers along the entire cancer care journey from screening to survivorship.
  • The innovative products, technologies, and clinical research Varian will feature during this year's show reflect the company's evolution into a comprehensive cancer care company and commitment to helping care providers make more informed decisions at every point of the cancer care journey.
  • Connected Imaging: As a Siemens Healthineers company, Varian is enabling greater personalization of cancer care through multimodality imaging and connecting oncology teams with advanced imaging capabilities inside and outside the treatment vault.
  • With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care.

TAE Life Sciences to Sponsor Industry Theater Session on the Future of Precision Oncology at 2022 ASTRO Annual Meeting

Retrieved on: 
Tuesday, October 18, 2022
Research, Technology, Other Technology, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Neutron, News, Radiation, Neutron capture therapy of cancer, Sale, Therapy, American Society for Radiation Oncology, Neoplasm, Society, Patient, Industry, Senior, Technology, Cancer, Centre for Industry Education Collaboration, TLS, Radiation therapy, ASTRO, Protein Sciences, Economics, Health, Research, Boron, BNCT, Pharmaceutical industry, Medical imaging

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 22-26, 2022.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 22-26, 2022.
  • The Industry Theater session, A Glimpse into the Future: Biologically Targeted Radiotherapy will feature presentations by Sunil Krishnan, M.B.B.S., M.D., Professor, Radiation Oncology, UT Health Houston, Minesh P. Mehta, MD., Deputy Director & Chief of Radiation Oncology, Miami Cancer Institute and Art Raitano, Senior Director Protein Sciences, TAE Life Sciences.
  • Session Title: A Glimpse into the Future: Biologically Targeted Radiotherapy
    BNCT is one of the most exciting developments in radiation therapy, and yet it remains inadequately explored in the clinic due to technological and pharmacological limitations.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, NASDAQ, Standard of care, Awareness, Data, AI, Deep inspiration breath-hold, CEO, Calibration, YouTube, Twitter, Symposium, Annual general meeting, Cancer, Private Securities Litigation Reform Act, National Cancer Institute, Industry, ASTRO, Breast cancer, TPS, CE, Breast Cancer Awareness Month, Time, Woman, Diagnosis, Solution, Annual report, Society, Security (finance), Radiation therapy, Artemis, U.S. Securities and Exchange Commission, National, Radiation, DIBH, Risk, Disease, Sale, SEC, Workflow, Neoplasm, Patient, Hospital, Partnership, American Society for Radiation Oncology, RaySearch Laboratories, Safety, Forward-looking statement, Heart, COVID-19, 2022 Formula One World Championship, Medical imaging, Medical device, Facebook, Software

Meeting attendees are invited to attend the U.S. unveiling of a new breast cancer treatment package* for the Radixact System at the Accuray booth, #2586, on Sunday, October 23, 2022 at 10:30 am CT.

Key Points: 
  • Meeting attendees are invited to attend the U.S. unveiling of a new breast cancer treatment package* for the Radixact System at the Accuray booth, #2586, on Sunday, October 23, 2022 at 10:30 am CT.
  • According to the National Cancer Institute, breast cancer is the most common cancer diagnosed in women in the U.S., other than skin cancers1.
  • Treatment for breast cancer represents more than 20 percent of cases seen by radiation oncology departments3,4.
  • The breast cancer treatment package [name to be revealed during the unveiling at ASTRO] is not available for sale in the USA.

Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Monday, September 26, 2022
SBRT, Therapy, Health, Safety, COVID-19, Otorhinolaryngology, Mucositis, Peripheral, NSCLC, GC4419, LAPC, Privacy, Early Stage, Annual general meeting, Pancreatic cancer, Society, Chemoradiotherapy, American Society for Radiation Oncology, Neoplasm, Cancer, Ownership, 2021 Essex County Council election, CDT, Annual report, Nasdaq, Private Securities Litigation Reform Act, ASTRO, AESOP, Radiation therapy, Large-cell lung carcinoma, SOM, GLOBE, SEC, Failure, Central neurogenic hyperventilation, Pharmaceutical industry, Patient

Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.

Key Points: 
  • Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
  • Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
  • Galeras selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.